Adherence, Efficacy and Tolerance of Once-a-day Nevirapine-based Regimen in HIV-1 Infected Patients

University Hospital, Caen0 sites62 target enrollmentJune 2004

ConditionsHIV Infections

Overview

Phase: Phase 4
Intervention: Not specified
Conditions: HIV Infections
Sponsor: University Hospital, Caen
Enrollment: 62
Primary Endpoint: MEMS adherence by electronic devices
Status: Completed
Last Updated: 15 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

Taking antiretrovirals once-a-day is considered the simpler way to improve adherence. However, it is not know if this assertion apply to patients taking their medication twice-a-day who change to once-a-day.

We hypothesized that once-daily dosing improves adherence.

Registry

clinicaltrials.gov

Start Date

June 2004

End Date

November 2006

Last Updated

15 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

University Hospital, Caen

Eligibility Criteria

Inclusion Criteria

•HIV-1 infected adults receiving antiretroviral therapy including nevirapine twice-a-day for at least 6 months
•plasma HIV RNA\<400 cp/ml during the previous 4 months on 2 occasions
•accept adherence electronic monitoring
•written informed consent signed

Exclusion Criteria

•asparate aminotransferase (AST) or alanine aminotransferase (ALT) \>2.5N if hepatitis virus B or C were negative
•AST or ALT\>1.25N if hepatitis virus B or C were positive